APG-1387 | 1570231-89-8

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: APG-1387
• 英文别名: Apg-1387；(5S,8S,10aR)-3-[3-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]sulfonyl]phenyl]sulfonyl-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
• CAS: 1570231-89-8
• 化学式: C₆₀H₇₂N₁₀O₁₀S₂
• 分子量: 1157.42
• InChiKey: AKLBERUGKZNEJY-RTEPGWBGSA-N

物化性质

• 密度：
  1.40±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：50 mg/mL（43.20 mM；需要超声波）|

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  82
• 可旋转键数：
  18
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  273
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20140057924A1

  公开（公告）日：2014-02-27

  Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed.

  抑制IAP蛋白质的抑制剂和含有这些抑制剂的组合物被披露。还披露了使用IAP蛋白质抑制剂治疗疾病和状况的方法，其中抑制IAP蛋白质提供益处，如癌症等。
• BISDIAZABICYCLO COMPOUND FOR TREATMENT AND/OR PREVENTION OF HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS
  申请人：JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.

  公开号：US20210290594A1

  公开（公告）日：2021-09-23

  Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
• METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US20210330642A1

  公开（公告）日：2021-10-28

  The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor.
• TREATMENT METHOD WITH IAP INHIBITOR
  申请人：Ascentage Pharma (Suzhou) Co., Ltd.

  公开号：US20220047606A1

  公开（公告）日：2022-02-17

  Improved methods for treating hepatitis B (HB) in patients with (5S,5′S,8S,8′S,10aR,10a′R)-3,3′-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) (Compound (I)) are disclosed herein. Dosing regimens of Compound (I) for the treatment of HBV infection are provided.
• US8883771B2
  申请人：——

  公开号：US8883771B2

  公开（公告）日：2014-11-11